Theriva Biologics, Inc. (TOVX) Financials

TOVX Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 34.9 million 22.7 million
March 31, 2026 38.2 million 22.8 million
Dec. 31, 2025 38.2 million 22.9 million
Sept. 30, 2025 30.8 million 24.1 million

TOVX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -2.7 million 135000
March 31, 2026 -2.5 million 135000
Dec. 31, 2025 -2.9 million 153000
Sept. 30, 2025 -4.3 million 228000

TOVX Net Income

No data available :(

TOVX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 11.3 million 1.6 million 1.4 million
March 31, 2026 14.4 million 1.6 million 1.5 million
Dec. 31, 2025 13.1 million 1.7 million 352000
Sept. 30, 2025 7.5 million 1.7 million 433000

TOVX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 45.9 million
March 31, 2026 41.1 million
Dec. 31, 2025 12.1 million
Sept. 30, 2025 9.7 million

TOVX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 3000 1.3 million 2.0 million -
March 31, 2026 - 355000 2.1 million -
Dec. 31, 2025 - 1.1 million 931000 -
Sept. 30, 2025 19000 2.6 million 1.9 million -

TOVX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 300000 24000
Dec. 31, 2025 - 27000
Sept. 30, 2025 - -

TOVX

Price: $0.20

52 week price:
0.16
0.86

Earnings Per Share: 1.44 USD

P/E Ratio: 0.16

Exchange: ASE

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 10.3 million

Links: